AI Insight
This study analyzed Lassa fever surveillance data from Nigeria between 2017-2026 and found that the reported increase in case fatality ratio from 18.9% to 25.0% was not due to deteriorating clinical care but rather to surveillance artifacts. Specifically, 70 deaths were added retrospectively to cumulative totals outside of weekly reports by week 36 of 2026, artificially inflating the fatality rate. When comparing weekly incident counts at phase-matched time points, there was no significant difference in case fatality ratios between 2025 and 2026.
Why it matters
The findings highlight critical gaps in disease surveillance systems for endemic zoonotic diseases, demonstrating that case fatality ratios cannot serve as reliable clinical outcome measures without transparent reporting of testing volumes, retrospectively added deaths, and post-mortem sampling practices. This has important implications for public health response and resource allocation decisions that rely on accurate mortality data.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Background. Nigeria’s reported Lassa fever case fatality ratio (CFR) rose from 18.9% at week 23 of 2025 to 25.0% in 2026, prompting concerns over failing clinical care. Because surveillance artefacts can also alter CFRs, candidate mechanisms that published data can resolve were identified and evaluated. Methods. This ecological study extracted weekly state-level counts from 474 Nigeria Centre for Disease Control and Prevention situation reports (2017-2026). Per a pre-specified plan, years were compared at phase-matched points, year-on-year CFR changes were decomposed into within-state and between-state components, and tipping-point ascertainment shifts calculated. Weekly incident and cumulative published totals were compared post hoc. Findings. Of 11 candidate mechanisms, 2 could be evaluated fully and 5 in part. On weekly incident counts, 2026 did not differ from 2025 at the phase-matched midpoint (+0.3 percentage points, 95% CI -5.0 to 7.6); within-state (-1.1, 95% CI -4.7 to 3.0) and between-state (+0.5, -2.0 to 2.9) components spanned zero. Conversely, the published cumulative CFR was 5.4 to 6.2 percentage points higher because 70 deaths were added retrospectively by week 36 outside weekly reports. Reconciling cumulative figures would require 279 missed survivors (6% of suspected cases not confirmed). Interpretation. The 2026 CFR rise came from deaths added to cumulative totals outside the weekly counts, and published data cannot attribute it to care. Endemic zoonotic CFRs cannot serve as clinical outcome measures unless testing volumes, deaths added late, and post-mortem sampling are published alongside case counts. Funding. US NSF-NIH-NIFA EEID; UK BBSRC; Birgitta Sintring Fellowship (Uppsala University).